Medical Filtration Market by Material (Polyethersulfone; Polyvinylidenefluoride), Applications (Dialysis; Sterile Processing), Process Technology (Ultrafiltration; Microfiltration), Design/Process, End-Users & Region - Global Forecast to 2030
의료용 여과 시장 규모는 6.8%의 연평균 복합 성장률(CAGR)로 확대되어 2024년 62억 9,000만 달러에서 2030년 93억 5,000만 달러에 달할 것으로 예상됩니다.
특히 의료 서비스 제공업체 및 연구 기관은 효과적인 제품과 함께 환자의 안전을 우선시하기 때문에 고품질 여과 솔루션에 대한 긴급한 수요가 이 시장의 큰 원동력이 되고 있습니다. 따라서 오염 물질의 제거를 보장하는 첨단 여과 기술이 가장 중요한 요소로 떠오르고 있습니다. 이러한 추세는 엄격한 규제 기준과 의료 현장에서 무균 환경 유지의 중요성이 높아짐에 따라 크게 영향을 받고 있습니다. 또한, 실험실 내 만성 질환 증가로 인해 임상 및 진단을 지원하는 신뢰할 수 있는 여과 시스템에 대한 수요도 증가하고 있습니다. 따라서 기업들은 이러한 진화하는 요구에 부응하는 특수 여과 제품을 혁신하고 개발하여 시장 입지를 강화하고 미래 성장을 가속할 수 있는 충분한 기회를 얻고 있습니다.
| 조사 범위 |
| 조사 대상 연도 |
2021-2030년 |
| 기준 연도 |
2023년 |
| 예측 기간 |
2024-2030년 |
| 대상 대수 |
대수, 금액(100만 달러) |
| 부문 |
재료별, 공정기술별, 설계/공정별, 최종사용자별, 용도별, 지역별 |
| 대상 지역 |
아시아태평양, 북미, 유럽, 중동/아프리카, 남미,기 타 지역 |
PVDF는 뛰어난 내화학성, 높은 열 안정성, 우수한 기계적 특성으로 인해 의료용 여과 시장에서 두 번째로 빠르게 성장하는 소재입니다. 이러한 특성으로 인해 PVDF는 무균 여과 및 멤브레인 기반 장비와 같은 까다로운 의료 응용 분야에 매우 적합합니다. PVDF는 오토클레이브 및 감마선 조사 등 다양한 멸균 기술과의 호환성으로 인해 의료용 여과에 매우 유용합니다. 또한 소수성 및 강력한 세정제에 대한 내성이 있기 때문에 점점 더 많은 인기를 얻고 있습니다. 의료 및 바이오프로세스 기술의 발전과 함께 강력하고 효율적인 여과 재료에 대한 수요가 증가함에 따라 PVDF의 채택이 증가하고 있습니다.
의료용 여과 시장의 가장 큰 시장 점유율은 감염 예방과 환자 안전에 대한 역할로 인해 병원이 차지하고 있습니다. 실제로 만성질환의 급증, 수술, 고령화 등으로 인한 입원 환자 수 증가는 고급 여과 시스템에 대한 수요를 증가시키고 있습니다. 병원은 인공호흡기, 정맥주입 시스템, 수술기구를 포함한 의료기기의 무균 공기와 물 측면에서 여과 솔루션에 크게 의존하고 있습니다. 엄격한 규제 기준을 충족해야 할 필요성과 함께 병원 내 감염 관리의 성장은 채택을 더욱 확대할 것으로 보입니다. 또한, 많은 신흥 경제국에서 의료 인프라가 개발되고 있으며, 병원이 최종 사용 산업에서 선두를 달리고 있습니다.
북미가 의료용 여과 시장에서 가장 큰 점유율을 차지하고 있는 이유는 의료 인프라가 발달하고, 규제 기준이 엄격하며, 의료 서비스에 대한 지출이 많기 때문입니다. 또한, 이 지역에는 많은 의료용 여과 제조 대기업이 존재하며, 고급 여과 솔루션에 대한 높은 수요도 이 시장을 견인하고 있습니다. 인구 고령화와 함께 만성 질환의 유행이 증가함에 따라 병원, 검사실, 재택치료에서 더 많은 여과 시스템이 필요하게 되었습니다. 북미에서도 볼 수 있듯이, 코로나19 이후 감염 관리로 인해 첨단 여과 기술의 사용이 더욱 가속화되고 있습니다. 아시아태평양은 급속한 도시화, 의료 인프라의 성장, 의료 산업에 대한 투자 증가에 힘입어 의료용 여과의 급성장 시장으로 부상하고 있습니다. 인구 증가와 고령화, 의료 위생에 대한 인식의 향상과 함께 의료용 여과 제품의 소비를 촉진하고 있습니다. 중국과 인도는 정부와 의료 관광이 국가의 급격한 성장을 견인하고 있기 때문에 중요한 신흥 경제 국가입니다.
세계의 의료용 여과 시장에 대해 조사했으며, 재료별/공정 기술별/설계 및 공정별/최종사용자별/용도별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 프리미엄 인사이트
제5장 시장 개요
- 서론
- 시장 역학
- Porter의 Five Forces 분석
- 주요 이해관계자와 구입 기준
- 거시경제 전망
- AI/생성형 AI의 영향
- 밸류체인 분석
- 생태계 분석
- 사례 연구 분석
- 관세 및 규제 상황
- 기술 분석
- 고객의 비즈니스에 영향을 미치는 동향/혼란
- 무역 분석
- 2025-2026년 주요 컨퍼런스 및 이벤트
- 가격 분석
- 투자와 자금조달 시나리오
- 특허 분석
제6장 의료용 여과 시장(재료별)
- 서론
- 폴리설폰 및 폴리에테르술폰
- 폴리 불화 비닐리덴
- 폴리테트라플루오로에틸렌
- 폴리프로필렌
- 기타
제7장 의료용 여과 시장(프로세스 기술별)
- 서론
- 한외 여과
- 마이크로 여과
- 나노 여과
- 역삼투
- 가스 여과
- 기타
제8장 의료용 여과 시장(설계/프로세스별)
- 서론
- 시스템(RTU 유닛)
- 여과 모듈(소모품)
- 기타
제9장 의료용 여과 시장(최종사용자별)
제10장 의료용 여과 시장(용도별)
- 서론
- 투석
- 약물전달
- IV 수액 및 멸균 여과
- 내시경 검사
- 멸균 처리
- 바이오 인공 프로세스
- 기타
제11장 의료용 여과 시장(지역별)
- 서론
- 아시아태평양
- 유럽
- 북미
- 중동 및 아프리카
- 남미
제12장 경쟁 구도
- 개요
- 주요 시장 진출기업의 전략/강점
- 매출 분석, 2021년-2023년
- 시장 점유율 분석, 2023년
- 기업 가치 평가와 재무 지표
- 제품 비교
- 기업 평가 매트릭스 : 주요 시장 진출기업, 2023년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
- 경쟁 시나리오
제13장 기업 개요 - 의료용 여과 장비 프로바이더
- 주요 시장 진출기업
- MERCK KGAA
- 3M(SOLVENTUM)
- DANAHER
- SARTORIUS AG
- ASAHI KASEI CORPORATION
- BAXTER
- THERMO FISHER SCIENTIFIC INC.
- VEOLIA
- DONALDSON COMPANY, INC.
- PARKER HANNIFIN CORP
- ENTEGRIS
- MANN+HUMMEL
- 기타 기업
- CORNING INCORPORATED
- CRITICAL PROCESS FILTRATION, INC.
- COBETTER
- GRAVER TECHNOLOGIES
- ERTELALSOP
- KASAG SWISS AG
- FILTROX AG
- MEMBRANE SOLUTIONS
- COLE-PARMER INSTRUMENT COMPANY, LLC
- MEISSNER FILTRATION PRODUCTS, INC.
- MEDICAL FILTRATION SOLUTIONS LTD.
- SEFAR AG
- WALKER FILTRATION
- SAINT-GOBAIN
제14장 기업 개요 -자 동 내시경 리프로세서 프로바이더.
- 주요 시장 진출기업
- STERIS
- FORTIVE
- OLYMPUS CORPORATION
- ECOLAB
- GETINGE
- STEELCOBELIMED(METALL ZUG GROUP)
- ENDO-TECHNIK W. GRIESAT(CREO)
- WASSENBURG MEDICAL B.V.(HOYA CORPORATION)
제15장 기업 개요 - 투석 장비 프로바이더
- 주요 시장 진출기업
- FRESENIUS MEDICAL CARE AG
- BAXTER
- DAVITA INC.
- NIKKISO CO., LTD.
- B. BRAUN SE
- NIPRO
- TORAY MEDICAL CO., LTD.
- MEDIONICS
제16장 부록
LSH
The medical filtration market is projected to reach USD 9.35 billion by 2030 from USD 6.29 billion in 2024, at a CAGR of 6.8%. The urgent demand for quality filtration solutions serves as a major driving force for this market, especially with healthcare providers and research institutions prioritizing patient safety along with effective products. Advanced filtration technologies that ensure the removal of contaminants have therefore become paramount. This trend is majorly influenced by stringent regulatory standards and rising importance of maintaining sterile environments in medical settings. There is also growing demand for reliable filtration systems to support clinical and diagnostics applications, supported by the increase in chronic diseases in laboratories. Hence, the companies have ample opportunities to innovate and develop specialized filtration products catering to such evolving needs and enhancing their market presence and driving future growth.
| Scope of the Report |
|---|
| Years Considered for the Study | 2021-2030 |
| Base Year | 2023 |
| Forecast Period | 2024-2030 |
| Units Considered | Units; Value (USD Million) |
| Segments | Material, Process Technology, Design/Process, Application and End-Users |
| Regions covered | Asia Pacific, North America, Europe, Middle East & Africa, and South America |
"Based on material, PVDF is the second fastest growing material in medical filtration market during the forecast period, in terms of value."
PVDF is the second-fastest-growing material in the medical filtration market due to its exceptional chemical resistance, high thermal stability, and excellent mechanical properties. These properties make it very suitable for demanding medical applications like sterile filtration and membrane-based devices. Compatibility with a wide range of sterilization techniques such as autoclaving and gamma radiation makes PVDF highly useful in medical filtration. Its hydrophobic nature and resistance to aggressive cleaning agents also make it increasingly popular. As healthcare and bioprocessing technologies advance, the demand for strong and efficient filtration materials grow increasing the adoption of PVDF .
"Based on end-use industry, hospitals account the largest share in medical filtration market during the forecast period, in terms of value."
The largest market share of the medical filtration market is captured by hospitals due to their role in infection prevention and patient safety. In fact, rising hospital admissions on account of surging chronic diseases, surgical procedures, and the aging population is boosting the demand for advanced filtration systems. Hospitals rely heavily on filtration solutions in terms of sterile air and water for medical devices including ventilators, IV infusion systems, and surgical tools. Growth in infection control in hospitals coupled with the necessity to meet severe regulatory standards leads to further growth in adoption. Moreover, developing healthcare infrastructure in many emerging economies contributes to hospitals' being the top end-use industry.
"Based on region, North America accounts the largest share and Asia pacific is the fastest growing region in medical filtration market, in terms of value."
North America accounts the largest share in medical filtration market majorly because of its developed healthcare infrastructure, strict regulatory standards, and high expenditure on healthcare services. This is further fueled by significant presence of major medical filtration manufacturing companies in the region with high demands for advanced filtration solutions. Increased prevalence of chronic diseases along with an aging population has created a need for more filtration systems within hospitals, laboratories, and in home care. Infection control, as also seen within the North America, has further added to the use of advanced filtration technologies following COVID-19. Asia Pacific is a rapidly growing market for medical filtration, supported by rapid urbanization, expansive healthcare infrastructure growth, and the increasing investments being made in medical industries. Its large and aging population, with improved awareness of healthcare hygiene, encourages the consumption of medical filtration products. China and India are significant emerging economies since the governments and medical tourism drive the country to grow more rapidly.
In the process of determining and verifying the market size for several segments and subsegments identified through secondary research, extensive primary interviews were conducted. A breakdown of the profiles of the primary interviewees are as follows:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: Directors- 35%, Managers - 25%, and Others - 40%
- By Region: North America - 22%, Europe - 22%, Asia Pacific - 45%, RoW - 11%
The key players in this market are Merck KGaA (Germany), 3M (Solventum) (US), Danaher (US), Sartorius AG (Germany), Veolia (France), Thermo Fisher Scientific Inc (US), Donaldson Company Inc (US), Baxter (US), Parker Hannifin Corp (US), Entegris (US), Asahi Kasei Corporation (Japan), and Mann+Hummel (Germany).
Research Coverage
This report segments the medical filtration market based on material, process technology, design/process, application, end-use industry, and region, and provides estimations for the overall value of the market across various regions. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, products and services, key strategies, new product launches, expansions, and mergers and acquisitions associated with the medical filtration market.
Key benefits of buying this report
This research report focuses on various levels of analysis, including industry analysis (industry trends), market ranking analysis of top players, and company profiles, which together provide an overall view of the competitive landscape, emerging and high-growth segments of the medical filtration market, high-growth regions, and market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing demand for high quality filtration solutions, Regulatory and quality standards and Growing focus on infection control), restraints (High cost of advanced filtration systems), opportunities (Growing healthcare investment in emerging economies and Advancements in filtration technologies) and challenges (Disposal of filters and Product performance variability).
- Market Penetration: Comprehensive information on the medical filtration market offered by top players in the global medical filtration market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the medical filtration market.
- Market Development: Comprehensive information about lucrative emerging markets - the report analyzes the markets for medical filtration market across regions.
- Market Diversification: Exhaustive information about new products, untapped regions, and recent developments in the global medical filtration market
- Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of leading players in the medical filtration market
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.3.5 UNITS CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 List of key secondary sources
- 2.1.1.2 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Key data from primary sources
- 2.1.2.2 List of key primary interview participants
- 2.1.2.3 Key industry insights
- 2.1.2.4 Breakdown of interviews with experts
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 BOTTOM-UP APPROACH
- 2.2.2 TOP-DOWN APPROACH
- 2.3 GROWTH FORECAST
- 2.4 DATA TRIANGULATION
- 2.5 FACTOR ANALYSIS
- 2.6 RESEARCH ASSUMPTIONS
- 2.7 RESEARCH LIMITATIONS AND RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MEDICAL FILTRATION MARKET
- 4.2 MEDICAL FILTRATION MARKET, BY MATERIAL
- 4.3 MEDICAL FILTRATION MARKET, BY APPLICATION
- 4.4 MEDICAL FILTRATION MARKET, BY END USER
- 4.5 MEDICAL FILTRATION MARKET, BY KEY COUNTRY
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Increasing demand for advanced healthcare solutions
- 5.2.1.2 Rising awareness of infection control
- 5.2.1.3 Technological advancements
- 5.2.2 RESTRAINTS
- 5.2.2.1 High capital investments
- 5.2.2.2 Stringent regulatory compliance
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Growing healthcare investments in emerging economies
- 5.2.3.2 Adoption of single-use technologies
- 5.2.4 CHALLENGES
- 5.2.4.1 Speed and yield issues
- 5.3 PORTER'S FIVE FORCES ANALYSIS
- 5.3.1 THREAT OF NEW ENTRANTS
- 5.3.2 THREAT OF SUBSTITUTES
- 5.3.3 BARGAINING POWER OF SUPPLIERS
- 5.3.4 BARGAINING POWER OF BUYERS
- 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.4 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.4.2 QUALITY
- 5.4.3 SERVICE
- 5.5 MACROECONOMIC OUTLOOK
- 5.5.1 GDP TRENDS AND FORECASTS
- 5.6 IMPACT OF AI/GEN AI
- 5.7 VALUE CHAIN ANALYSIS
- 5.7.1 RAW MATERIAL SUPPLIERS
- 5.7.2 MANUFACTURERS
- 5.7.3 DISTRIBUTORS
- 5.7.4 END USERS
- 5.8 ECOSYSTEM ANALYSIS
- 5.9 CASE STUDY ANALYSIS
- 5.9.1 VALIDATING PEGASUS PRIME VIRUS REMOVAL FILTERS WITH PREFILTERS
- 5.9.2 ENHANCING DIALYSIS FILTRATION EFFICIENCY - FRESENIUS MEDICAL CARE
- 5.9.3 BLOOD FILTRATION FOR SEPSIS TREATMENT - CYTOSORBENTS CORPORATION
- 5.10 TARIFF AND REGULATORY LANDSCAPE
- 5.10.1 ENVIRONMENTAL REGULATIONS
- 5.10.2 NORTH AMERICA
- 5.10.3 ASIA PACIFIC
- 5.10.4 EUROPE
- 5.10.5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.11 TECHNOLOGY ANALYSIS
- 5.11.1 KEY TECHNOLOGIES
- 5.11.1.1 Microfiltration
- 5.11.1.2 Ultrafiltration
- 5.11.1.3 Nanofiltration
- 5.11.2 COMPLEMENTARY TECHNOLOGIES
- 5.11.2.1 Single-use technology
- 5.11.3 ADJACENT TECHNOLOGIES
- 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.13 TRADE ANALYSIS
- 5.13.1 EXPORT SCENARIO (HS CODE 8421)
- 5.13.2 IMPORT SCENARIO (HS CODE 8421)
- 5.14 KEY CONFERENCES AND EVENTS, 2025-2026
- 5.15 PRICING ANALYSIS
- 5.15.1 AVERAGE SELLING PRICE TREND, BY REGION, 2021-2023
- 5.15.2 AVERAGE SELLING PRICE TREND, BY APPLICATION, 2021-2023
- 5.15.3 AVERAGE SELLING PRICE TREND, BY END USER, 2021-2023
- 5.16 INVESTMENT AND FUNDING SCENARIO
- 5.17 PATENT ANALYSIS
- 5.17.1 INTRODUCTION
- 5.17.2 LEGAL STATUS OF PATENTS
- 5.17.3 JURISDICTION ANALYSIS
6 MEDICAL FILTRATION MARKET, BY MATERIAL
- 6.1 INTRODUCTION
- 6.2 POLYSULFONE & POLYETHERSULFONE
- 6.2.1 EXCELLENT MECHANICAL STRENGTH, THERMAL STABILITY, AND CHEMICAL RESISTANCE TO BOOST MARKET
- 6.3 POLYVINYLIDENE FLUORIDE
- 6.3.1 EXCEPTIONAL CHEMICAL RESISTANCE, THERMAL STABILITY, AND MECHANICAL STRENGTH TO DRIVE MARKET
- 6.4 POLYTETRAFLUOROETHYLENE
- 6.4.1 SUPERIOR FILTRATION PERFORMANCE IN CRITICAL MEDICAL APPLICATIONS TO PROPEL DEMAND
- 6.5 POLYPROPYLENE
- 6.5.1 EXCELLENT CHEMICAL RESISTANCE, DURABILITY, AND COST-EFFECTIVENESS TO DRIVE DEMAND
- 6.6 OTHER MATERIALS
7 MEDICAL FILTRATION MARKET, BY PROCESS TECHNOLOGY
- 7.1 INTRODUCTION
- 7.2 ULTRAFILTRATION
- 7.2.1 INCREASING PREVALENCE OF CHRONIC KIDNEY DISEASE AND RISING DEMAND FOR DIALYSIS TREATMENTS TO BOOST MARKET
- 7.3 MICROFILTRATION
- 7.3.1 GROWING USAGE IN STERILIZATION, WATER PURIFICATION, AND BIOPHARMACEUTICAL MANUFACTURING TO DRIVE DEMAND
- 7.4 NANOFILTRATION
- 7.4.1 LOW ENERGY CONSUMPTION AND HIGH FILTRATION EFFICIENCY TO SUPPORT MARKET GROWTH
- 7.5 REVERSE OSMOSIS
- 7.5.1 CRUCIAL ROLE IN ENSURING SAFETY OF WATER IN MEDICAL PROCEDURES TO BOOST MARKET
- 7.6 GAS FILTRATION
- 7.6.1 DELIVERY OF HIGH-QUALITY FILTERED AIR TO FUEL GROWTH
- 7.7 OTHER PROCESS TECHNOLOGIES
8 MEDICAL FILTRATION MARKET, BY DESIGN/PROCESS
- 8.1 INTRODUCTION
- 8.2 SYSTEMS (RTU UNITS)
- 8.2.1 CONVENIENCE, TIME-SAVING BENEFITS, AND ABILITY TO ENSURE CONSISTENT FILTRATION PERFORMANCE TO BOOST MARKET
- 8.3 FILTRATION MODULES (CONSUMABLES)
- 8.3.1 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE DEMAND FOR FILTRATION MODULES IN HEALTHCARE
- 8.4 OTHER DESIGNS/PROCESSES
9 MEDICAL FILTRATION MARKET, BY END USER
- 9.1 INTRODUCTION
- 9.2 HOSPITALS
- 9.2.1 REQUIREMENT OF HIGH-PURITY WATER FOR WOUND CARE, SURGICAL PROCEDURES, STERILIZATION, AND DIALYSIS TO DRIVE MARKET
- 9.3 DIAGNOSTIC CENTERS
- 9.3.1 DEMAND FOR HIGH-PURITY WATER, FLUIDS, AND AIR TO ENSURE RELIABLE DIAGNOSTICS TO DRIVE GROWTH
- 9.4 RESEARCH INSTITUTES
- 9.4.1 INCREASE IN BIOLOGICAL STUDIES, AND MEDICAL RESEARCH TO BOOST MARKET
- 9.5 OTHER END USERS
10 MEDICAL FILTRATION MARKET, BY APPLICATION
- 10.1 INTRODUCTION
- 10.2 DIALYSIS
- 10.2.1 ACCURACY AND OPERATIONAL FILTRATION EFFICIENCY IN BLOOD PURIFICATION TO BOOST GROWTH
- 10.3 DRUG DELIVERY
- 10.3.1 PROVISION OF OPTIMAL CONDITIONS THROUGH CONSISTENT FLOW RATES AND MINIMUM PRESSURE DROPS TO FUEL MARKET GROWTH
- 10.4 IV INFUSION & STERILE FILTRATION
- 10.4.1 HIGH LEVEL OF PRECISION IN CONTAMINANT REMOVAL WHILE PRESERVING FLUID INTEGRITY TO DRIVE GROWTH
- 10.5 ENDOSCOPY
- 10.5.1 ENHANCEMENT OF SAFETY AND PERFORMANCE WITH ADVANCED FILTRATION TO BOOST MARKET
- 10.6 STERILE PROCESSING
- 10.6.1 GROWING DEMAND FOR SURGICAL INSTRUMENTS, ENDOSCOPES, AND REUSABLE MEDICAL DEVICES TO PROPEL MARKET
- 10.7 BIO-ARTIFICIAL PROCESSES
- 10.7.1 VITAL ROLE OF SOPHISTICATED FILTRATION SYSTEMS IN DEVELOPMENT AND FUNCTIONALITY OF BIO-ARTIFICIAL ORGANS TO BOOST MARKET
- 10.8 OTHER APPLICATIONS
11 MEDICAL FILTRATION MARKET, BY REGION
- 11.1 INTRODUCTION
- 11.2 ASIA PACIFIC
- 11.2.1 CHINA
- 11.2.1.1 Strong economic growth and expanding healthcare sector to drive market
- 11.2.2 JAPAN
- 11.2.2.1 Growing aging population to propel market
- 11.2.3 INDIA
- 11.2.3.1 Increasing investments in healthcare sector to drive market
- 11.2.4 SOUTH KOREA
- 11.2.4.1 Rising demand for high-quality medical filtration solutions to drive market
- 11.2.5 REST OF ASIA PACIFIC
- 11.3 EUROPE
- 11.3.1 GERMANY
- 11.3.1.1 Economic strength, increasing healthcare expenditure, and rapidly aging population to drive market
- 11.3.2 UK
- 11.3.2.1 Rising geriatric population to support market growth
- 11.3.3 FRANCE
- 11.3.3.1 Aging population and enhancement of healthcare system to propel market
- 11.3.4 ITALY
- 11.3.4.1 Growing aging population to increase demand
- 11.3.5 SPAIN
- 11.3.5.1 Rising demand for advanced medical solutions to propel market
- 11.3.6 REST OF EUROPE
- 11.4 NORTH AMERICA
- 11.4.1 US
- 11.4.1.1 Stringent regulatory guidelines and increasing healthcare spending to boost market
- 11.4.2 CANADA
- 11.4.2.1 Growing aging population and significant government investments in healthcare infrastructure to drive market growth
- 11.4.3 MEXICO
- 11.4.3.1 Government initiatives and growth of healthcare sector to drive market
- 11.5 MIDDLE EAST & AFRICA
- 11.5.1 GCC COUNTRIES
- 11.5.1.1 Saudi Arabia
- 11.5.1.1.1 Economic growth, increasing government investments, and rising healthcare expenditures to drive market
- 11.5.1.2 Rest of GCC Countries
- 11.5.2 SOUTH AFRICA
- 11.5.2.1 Outbreaks of contagious diseases to drive demand
- 11.5.3 REST OF MIDDLE EAST & AFRICA
- 11.6 SOUTH AMERICA
- 11.6.1 BRAZIL
- 11.6.1.1 Rising healthcare investments and expanding medical infrastructure to propel growth
- 11.6.2 ARGENTINA
- 11.6.2.1 Increasing healthcare expenditure and enhancement of medical infrastructure to drive market
- 11.6.3 REST OF SOUTH AMERICA
12 COMPETITIVE LANDSCAPE
- 12.1 OVERVIEW
- 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 12.3 REVENUE ANALYSIS, 2021-2023
- 12.4 MARKET SHARE ANALYSIS, 2023
- 12.5 COMPANY VALUATION AND FINANCIAL METRICS
- 12.6 PRODUCT COMPARISON
- 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 12.7.1 STARS
- 12.7.2 EMERGING LEADERS
- 12.7.3 PERVASIVE PLAYERS
- 12.7.4 PARTICIPANTS
- 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 12.7.5.1 Region footprint
- 12.7.5.2 Material footprint
- 12.7.5.3 Process technology footprint
- 12.7.5.4 Design/Process footprint
- 12.7.5.5 Application footprint
- 12.7.5.6 End user footprint
- 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 12.8.1 PROGRESSIVE COMPANIES
- 12.8.2 RESPONSIVE COMPANIES
- 12.8.3 DYNAMIC COMPANIES
- 12.8.4 STARTING BLOCKS
- 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 12.8.5.1 Detailed list of key startups/SMEs
- 12.8.5.2 Competitive benchmarking of key startups/SMEs
- 12.9 COMPETITIVE SCENARIO
- 12.9.1 PRODUCT LAUNCHES
- 12.9.2 DEALS
- 12.9.3 EXPANSIONS
- 12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES - MEDICAL FILTRATION EQUIPMENT PROVIDERS
- 13.1 KEY PLAYERS
- 13.1.1 MERCK KGAA
- 13.1.1.1 Business overview
- 13.1.1.2 Products/Solutions/Services offered
- 13.1.1.3 Recent developments
- 13.1.1.4 MnM view
- 13.1.1.4.1 Right to win
- 13.1.1.4.2 Strategic choices
- 13.1.1.4.3 Weaknesses and competitive threats
- 13.1.2 3M (SOLVENTUM)
- 13.1.2.1 Business overview
- 13.1.2.2 Products/Solutions/Services offered
- 13.1.2.3 Recent developments
- 13.1.2.3.1 Other developments
- 13.1.2.4 MnM view
- 13.1.2.4.1 Right to win
- 13.1.2.4.2 Strategic choices
- 13.1.2.4.3 Weaknesses and competitive threats
- 13.1.3 DANAHER
- 13.1.3.1 Business overview
- 13.1.3.2 Products/Solutions/Services offered
- 13.1.3.3 Recent developments
- 13.1.3.3.1 Deals
- 13.1.3.3.2 Other developments
- 13.1.3.4 MnM view
- 13.1.3.4.1 Right to win
- 13.1.3.4.2 Strategic choices
- 13.1.3.4.3 Weaknesses and competitive threats
- 13.1.4 SARTORIUS AG
- 13.1.4.1 Business overview
- 13.1.4.2 Products/Solutions/Services offered
- 13.1.4.3 Recent developments
- 13.1.4.3.1 Product launches
- 13.1.4.4 MnM view
- 13.1.4.4.1 Right to win
- 13.1.4.4.2 Strategic choices
- 13.1.4.4.3 Weaknesses and competitive threats
- 13.1.5 ASAHI KASEI CORPORATION
- 13.1.5.1 Business overview
- 13.1.5.2 Products/Solutions/Services offered
- 13.1.5.3 MnM view
- 13.1.5.3.1 Right to win
- 13.1.5.3.2 Strategic choices
- 13.1.5.3.3 Weaknesses and competitive threats
- 13.1.6 BAXTER
- 13.1.6.1 Business overview
- 13.1.6.2 Products/Solutions/Services offered
- 13.1.6.3 Recent developments
- 13.1.6.4 MnM view
- 13.1.6.4.1 Right to win
- 13.1.6.4.2 Strategic choices
- 13.1.6.4.3 Weaknesses and competitive threats
- 13.1.7 THERMO FISHER SCIENTIFIC INC.
- 13.1.7.1 Business overview
- 13.1.7.2 Products/Solutions/Services offered
- 13.1.7.3 MnM view
- 13.1.8 VEOLIA
- 13.1.8.1 Business overview
- 13.1.8.2 Products/Solutions/Services offered
- 13.1.8.3 Recent developments
- 13.1.8.3.1 Product launches
- 13.1.8.4 MnM view
- 13.1.8.4.1 Right to win
- 13.1.8.4.2 Strategic choices
- 13.1.8.4.3 Weaknesses and competitive threats
- 13.1.9 DONALDSON COMPANY, INC.
- 13.1.9.1 Business overview
- 13.1.9.2 Products/Solutions/Services offered
- 13.1.9.3 Recent developments
- 13.1.9.4 MnM view
- 13.1.10 PARKER HANNIFIN CORP
- 13.1.10.1 Business overview
- 13.1.10.2 Products/Solutions/Services offered
- 13.1.10.3 MnM view
- 13.1.11 ENTEGRIS
- 13.1.11.1 Business overview
- 13.1.11.2 Products/Solutions/Services offered
- 13.1.11.3 MnM view
- 13.1.12 MANN+HUMMEL
- 13.1.12.1 Business overview
- 13.1.12.2 Products/Solutions/Services offered
- 13.1.12.3 MnM view
- 13.2 OTHER PLAYERS
- 13.2.1 CORNING INCORPORATED
- 13.2.2 CRITICAL PROCESS FILTRATION, INC.
- 13.2.3 COBETTER
- 13.2.4 GRAVER TECHNOLOGIES
- 13.2.5 ERTELALSOP
- 13.2.6 KASAG SWISS AG
- 13.2.7 FILTROX AG
- 13.2.8 MEMBRANE SOLUTIONS
- 13.2.9 COLE-PARMER INSTRUMENT COMPANY, LLC
- 13.2.10 MEISSNER FILTRATION PRODUCTS, INC.
- 13.2.11 MEDICAL FILTRATION SOLUTIONS LTD.
- 13.2.12 SEFAR AG
- 13.2.13 WALKER FILTRATION
- 13.2.14 SAINT-GOBAIN
14 COMPANY PROFILES - AUTOMATED ENDOSCOPE REPROCESSOR PROVIDERS
- 14.1 KEY PLAYERS
- 14.1.1 STERIS
- 14.1.1.1 Business overview
- 14.1.1.2 Products/Solutions/Services offered
- 14.1.1.3 Recent developments
- 14.1.1.4 MnM view
- 14.1.1.4.1 Right to win
- 14.1.1.4.2 Strategic choices
- 14.1.1.4.3 Weaknesses and competitive threats
- 14.1.2 FORTIVE
- 14.1.2.1 Business overview
- 14.1.2.2 Products/Solutions/Services offered
- 14.1.2.3 Recent developments
- 14.1.2.4 MnM view
- 14.1.2.4.1 Right to win
- 14.1.2.4.2 Strategic choices
- 14.1.2.4.3 Weaknesses and competitive threats
- 14.1.3 OLYMPUS CORPORATION
- 14.1.3.1 Business overview
- 14.1.3.2 Products/Solutions/Services offered
- 14.1.3.3 Recent developments
- 14.1.3.3.1 Product launches
- 14.1.3.4 MnM view
- 14.1.3.4.1 Right to win
- 14.1.3.4.2 Strategic choices
- 14.1.3.4.3 Weaknesses and competitive threats
- 14.1.4 ECOLAB
- 14.1.4.1 Business overview
- 14.1.4.2 Products/Solutions/Services offered
- 14.1.4.3 Recent developments
- 14.1.4.3.1 Product launches
- 14.1.4.4 MnM view
- 14.1.4.4.1 Right to win
- 14.1.4.4.2 Strategic choices
- 14.1.4.4.3 Weaknesses and competitive threats
- 14.1.5 GETINGE
- 14.1.5.1 Business overview
- 14.1.5.2 Products/Solutions/Services offered
- 14.1.5.3 Recent developments
- 14.1.5.4 MnM view
- 14.1.5.4.1 Right to win
- 14.1.5.4.2 Strategic choices
- 14.1.5.4.3 Weaknesses and competitive threats
- 14.1.6 STEELCOBELIMED (METALL ZUG GROUP)
- 14.1.6.1 Business overview
- 14.1.6.2 Products/Solutions/Services offered
- 14.1.6.3 Recent developments
- 14.1.6.4 MnM view
- 14.1.7 ENDO-TECHNIK W. GRIESAT (CREO)
- 14.1.7.1 Business overview
- 14.1.7.2 Products/Solutions/Services offered
- 14.1.7.3 MnM view
- 14.1.8 WASSENBURG MEDICAL B.V. (HOYA CORPORATION)
- 14.1.8.1 Business overview
- 14.1.8.2 Products/Solutions/Services offered
- 14.1.8.3 Recent developments
15 COMPANY PROFILES - DIALYSIS EQUIPMENT PROVIDERS
- 15.1 KEY PLAYERS
- 15.1.1 FRESENIUS MEDICAL CARE AG
- 15.1.1.1 Business overview
- 15.1.1.2 Products/Solutions/Services offered
- 15.1.1.3 Recent developments
- 15.1.1.3.1 Product launches
- 15.1.1.3.2 Deals
- 15.1.1.4 MnM view
- 15.1.1.4.1 Right to win
- 15.1.1.4.2 Strategic choices
- 15.1.1.4.3 Weaknesses and competitive threats
- 15.1.2 BAXTER
- 15.1.2.1 Business overview
- 15.1.2.2 Products/Solutions/Services offered
- 15.1.2.3 Recent developments
- 15.1.2.4 MnM view
- 15.1.2.4.1 Right to win
- 15.1.2.4.2 Strategic choices
- 15.1.2.4.3 Weaknesses and competitive threats
- 15.1.3 DAVITA INC.
- 15.1.3.1 Business overview
- 15.1.3.2 Products/Solutions/Services offered
- 15.1.3.3 Recent developments
- 15.1.3.3.1 Deals
- 15.1.3.3.2 Expansions
- 15.1.3.4 MnM view
- 15.1.3.4.1 Right to win
- 15.1.3.4.2 Strategic choices
- 15.1.3.4.3 Weaknesses and competitive threats
- 15.1.4 NIKKISO CO., LTD.
- 15.1.4.1 Business overview
- 15.1.4.2 Products/Solutions/Services offered
- 15.1.4.3 Recent developments
- 15.1.4.4 MnM view
- 15.1.4.4.1 Right to win
- 15.1.4.4.2 Strategic choices
- 15.1.4.4.3 Weaknesses and competitive threats
- 15.1.5 B. BRAUN SE
- 15.1.5.1 Business overview
- 15.1.5.2 Products/Solutions/Services offered
- 15.1.5.3 Recent developments
- 15.1.5.3.1 Product launches
- 15.1.5.3.2 Expansions
- 15.1.5.4 MnM view
- 15.1.5.4.1 Right to win
- 15.1.5.4.2 Strategic choices
- 15.1.5.4.3 Weaknesses and competitive threats
- 15.1.6 NIPRO
- 15.1.6.1 Business overview
- 15.1.6.2 Products/Solutions/Services offered
- 15.1.6.3 Recent developments
- 15.1.6.3.1 Product launches
- 15.1.7 TORAY MEDICAL CO., LTD.
- 15.1.7.1 Business overview
- 15.1.7.2 Products/Solutions/Services offered
- 15.1.8 MEDIONICS
- 15.1.8.1 Business overview
- 15.1.8.2 Products/Solutions/Services offered
16 APPENDIX
- 16.1 DISCUSSION GUIDE
- 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 16.3 CUSTOMIZATION OPTIONS
- 16.4 RELATED REPORTS
- 16.5 AUTHOR DETAILS
